A2 Biotherapeutics, Inc. | $80,000,000 | (Jan 10, 2025)
Holly | $2,200,000 | (Jan 10, 2025)
RLTYco | $20,000,000 | (Jan 10, 2025)
Light Horse Therapeutics
United States
- San Diego, California
- 10/01/2025
- Series A
- $62,000,000
Light Horse is leading the way in precision genome editing applied to small molecule drug discovery, pioneering approaches to target the root causes of disabling and life-threatening diseases. Its advanced platform identifies cryptic chemically accessible functional domains within targets that play critical roles in disease biology. The high-throughput discovery platform systematically interrogates complex signaling pathways to uncover unique sites of vulnerability. Light Horse interrogates these targets in their native, cellular context to best ensure that discoveries in the lab translate into the clinic. www.lighthorsetx.com
- Industry Biotechnology Research
- Website https://www.lighthorsetx.com/
- LinkedIn https://www.linkedin.com/company/light-horse-therapeutics/
Related People
Markus Renschler, MDFounder
United States -
San Diego, California
CEO experienced in building companies, raising capital in private and public markets, and developing oncology drugs. Led Cyteir from start-up to public clinical stage company. Board certified medical oncologist with 25 years’ experience in cancer research from basic laboratory research to drug approval and commercialization. Experienced in recruiting and motivating teams. Successful global registrations in breast cancer, non-small cell lung cancer and pancreatic cancer.
Air | $35,000,000 | (Jan 10, 2025)
Prudentia Sciences | $7,000,000 | (Jan 10, 2025)
Biosphere | $8,800,000 | (Jan 10, 2025)
RyboDyn Inc. | $4,000,000 | (Jan 10, 2025)
RheumaGen | $15,000,000 | (Jan 10, 2025)
Abstract(US) | $4,800,000 | (Jan 10, 2025)
PrettyDamnQuick | $25,000,000 | (Jan 10, 2025)
Oxford Cancer Analytics | $11,000,000 | (Jan 10, 2025)